Hypothesis: Atorvastatin Has Pleiotropic Effects that Translate into Early Clinical Benefits on Cardiovascular Disease

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 9, Issue 1, 2004, Pages 61-63

  Novela, Cristina ^a   Hennekens, Charles H ^b,c,d  

^a Miami Heart Inst   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Agatston Research Institute   (United States)

^d PH A   (United States)

Author keywords

Atorvastatin; Hypothesis; Pleiotropy

Indexed keywords

ATORVASTATIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVITY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; HEART INFARCTION; HUMAN; LIPID PEROXIDATION; PLEIOTROPY; PRIORITY JOURNAL; PROTECTION; THROMBOCYTE;

EID: 1942542158     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840400900i109     Document Type: Article

References (15)

1. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA 278:313-321, 1997
2. LaRosa JC, He J, Fvupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 282:2340-2346, 1999
3. 4S Investigators. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholestererol levels. N Engl J Med 335:1001-1009, 1996
5. Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998
6. Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361:1149-1158, 2003
7. Dahlof B, et al. Anglo-Scandinavian Cardiac Outcomes Trial. Am J Hypertens 1998:11:9A-10A
8. Serebruany VL, Midei MG, Malinin AI, et al. Atorvastatin does not affect the antiplatelet properties of clopidogrel in patients undergoing coronary stenting in The Interaction of Atorvastatin and Clopidogrel Study. Presented at the European Society of Cardiology, August 2003
9. Mason RP. Direct antioxidant effects of atorvastatin and an active metabolite: A comparative analysis. Circulation I-541, 1999 (abstract)
10. Xue-Qiao MC, Chait AZ, Albers JJ, et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 21:1, 2001
11. Eidelman RS, Lamas GA, Hennekens CH, The New NCEP Guidelines. Clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch Intern Med 162:2033-2036, 2002
12. Colhoun HM, Thomason MJ, Mackness MI, et al. The Collaborative Atorvastastin Diabetes Study. Diabet Med 19:201-211, 2002
13. Van Boven AJ, Liem AH, et al. Fluvastatin on risk diminishing after acute myocardial infarction (FLORIDA). Clin Cardiol 24:85-88, 2001
14. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL). JAMA 285:1711-1718, 2001
15. Nissen S, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, for the (REVERSAL Investigators). A prospective, randomized, double blind, multi-center study comparing the effects of atorvastatin vs. pravastatin on the progression of coronary atherosclerotic lesions as measured by intravascular ultrasound. Session XI: Late Breaking Clinical Trials, American Heart Association Scientific Sessions; Nov 9-12, 2003